- Home
- ENTX vs ORMP Comparison
ENTX vs ORMP Comparison
Compare ENTX & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTX
- ORMP
- Stock Information
- Founded
- ENTX 2010
- ORMP 2002
- Country
- ENTX Israel
- ORMP United States
- Employees
- ENTX N/A
- ORMP N/A
- Industry
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- ORMP Biotechnology: Pharmaceutical Preparations
- Sector
- ENTX Health Care
- ORMP Health Care
- Exchange
- ENTX Nasdaq
- ORMP Nasdaq
- Market Cap
- ENTX 104.0M
- ORMP N/A
- IPO Year
- ENTX 2018
- ORMP N/A
- Fundamental
- Price
- ENTX $1.72
- ORMP $2.15
- Analyst Decision
- ENTX Strong Buy
- ORMP Hold
- Analyst Count
- ENTX 1
- ORMP 1
- Target Price
- ENTX $10.00
- ORMP N/A
- AVG Volume (30 Days)
- ENTX 36.8K
- ORMP 63.0K
- Earning Date
- ENTX 08-08-2025
- ORMP 08-15-2025
- Dividend Yield
- ENTX N/A
- ORMP N/A
- EPS Growth
- ENTX N/A
- ORMP N/A
- EPS
- ENTX N/A
- ORMP N/A
- Revenue
- ENTX $223,000.00
- ORMP $2,000,000.00
- Revenue This Year
- ENTX N/A
- ORMP N/A
- Revenue Next Year
- ENTX N/A
- ORMP N/A
- P/E Ratio
- ENTX N/A
- ORMP N/A
- Revenue Growth
- ENTX N/A
- ORMP 196.74
- 52 Week Low
- ENTX $1.41
- ORMP $1.82
- 52 Week High
- ENTX $2.79
- ORMP $3.09
- Technical
- Relative Strength Index (RSI)
- ENTX 35.45
- ORMP 46.79
- Support Level
- ENTX $1.75
- ORMP $2.09
- Resistance Level
- ENTX $1.88
- ORMP $2.20
- Average True Range (ATR)
- ENTX 0.11
- ORMP 0.09
- MACD
- ENTX -0.02
- ORMP -0.00
- Stochastic Oscillator
- ENTX 0.00
- ORMP 36.84
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.